Trial Profile
A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Platinum complexes
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ICON6
- 30 Jul 2020 This trial was discontinued in United Kingdom, according to European Clinical Trials Database record.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 24 Mar 2017 Results of Quality of Life (QOL) sub-study published in the Cancer